A Cornell-led collaboration devised a potentially low-cost method for producing antibodies for therapeutic treatments: bioengineered bacteria with an overlooked enzyme that can help monoclonal antibodies boost their immune defenses.
Read the story in the Cornell Chronicle.
How to train a magnet: Excitons as a new knob for magnetic control
A&S Communications
